P. Meyers, Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate, Journal of Clinical Oncology, vol.23, issue.9, 2005.
DOI : 10.1200/JCO.2005.06.031

P. Meyers, C. Schwartz, M. Krailo, J. Healey, M. Bernstein et al., Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survivalea report from the Children's Oncology Group, J Clin Oncol Off J Am Soc Clin Oncol Feb, vol.126, issue.4, pp.633-641, 2008.

J. Whelan, S. Bielack, N. Marina, S. Smeland, G. Jovic et al., EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment???, Annals of Oncology, vol.26, issue.2, pp.407-421, 2015.
DOI : 10.1093/annonc/mdu526
URL : https://academic.oup.com/annonc/article-pdf/26/2/407/19480414/mdu526.pdf

S. Bielack, S. Smeland, J. Whelan, N. Marina, G. Jovic et al., Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial, Journal of Clinical Oncology, vol.33, issue.20, pp.2279-87, 2015.
DOI : 10.1200/JCO.2014.60.0734

M. Isakoff, S. Bielack, P. Meltzer, R. Gorlick, D. Mulrooney et al., Osteosarcoma: current treatment and a collaborative pathway to success Cardiac outcomes in adult survivors of childhood cancer exposed to cardiotoxic therapy: a crosssectional study, J Clin Oncol Ann Intern Med, vol.33164, issue.272, p.93, 2015.

T. Langer, Prospective evaluation of cisplatin-and carboplatinmediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients, Oncol Lett, 2012.

L. Deley, M. Guinebretière, J. Gentet, J. Pacquement, H. Pichon et al., SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients, European Journal of Cancer, vol.43, issue.4, pp.752-61, 2007.
DOI : 10.1016/j.ejca.2006.10.023

J. Anninga, H. Gelderblom, M. Fiocco, J. Kroep, A. Taminiau et al., Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?, European Journal of Cancer, vol.47, issue.16, pp.2431-2476, 2011.
DOI : 10.1016/j.ejca.2011.05.030

S. Piperno-neumann, L. Deley, M. Rédini, F. Pacquement, H. Marec-bérard et al., Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial, The Lancet Oncology, vol.17, issue.8, pp.1070-80, 2016.
DOI : 10.1016/S1470-2045(16)30096-1

M. Neyssa, M. , S. Sigbjørn, B. Stefan, S. et al., Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial, Lancet Oncol, 2016.

M. Collins, M. Wilhelm, R. Conyers, A. Herschtal, J. Whelan et al., Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis, Journal of Clinical Oncology, vol.31, issue.18, pp.2303-2315, 2013.
DOI : 10.1200/JCO.2012.43.8598

N. Omer, L. Deley, M. Piperno-neumann, S. Marec-berard, P. Italiano et al., Phase-II trials in osteosarcoma recurrences: A systematic review of past experience, European Journal of Cancer, vol.75, pp.98-108, 2017.
DOI : 10.1016/j.ejca.2017.01.005

D. Mulrooney, M. Yeazel, T. Kawashima, A. Mertens, P. Mitby et al., Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort, BMJ, vol.339, issue.dec08 1, 2009.
DOI : 10.1136/bmj.b4606

K. Henson, R. Reulen, D. Winter, C. Bright, M. Fidler et al., Cardiac Mortality Among 200???000 Five-Year Survivors of Cancer Diagnosed at 15 to 39 Years of AgeClinical Perspective, Circulation, vol.134, issue.20, pp.1519-1550, 2016.
DOI : 10.1161/CIRCULATIONAHA.116.022514

D. Brewster, D. Clark, L. Hopkins, J. Bauer, S. Wild et al., Subsequent hospitalisation experience of 5-year survivors of childhood, adolescent, and young adult cancer in Scotland: a population based, retrospective cohort study, British Journal of Cancer, vol.13, issue.5, pp.1342-50, 2014.
DOI : 10.1136/bmj.f1190

D. Mulrooney, K. Ness, S. Huang, A. Solovey, R. Hebbel et al., Pilot study of vascular health in survivors of osteosarcoma, Pediatric Blood & Cancer, vol.420, issue.10, pp.1703-1711, 2013.
DOI : 10.1038/nature01323

W. Stö-hr, T. Langer, A. Kremers, S. Bielack, A. Lamprecht-dinnesen et al., Cisplatin-Induced Ototoxicity in Osteosarcoma Patients: A Report from the Late Effects Surveillance System, Cancer Investigation, vol.22, issue.3, pp.201-208, 2005.
DOI : 10.1288/00005537-199007000-00008

E. Clemens, A. De-vries, S. Pluijm, A. Zehnhoff-dinnesen, W. Tissing et al., Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study, European Journal of Cancer, vol.69, pp.77-85, 2016.
DOI : 10.1016/j.ejca.2016.09.023

K. Knight, L. Chen, D. Freyer, R. Aplenc, M. Bancroft et al., Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children???s Oncology Group, Journal of Clinical Oncology, vol.35, issue.4, pp.440-445, 2016.
DOI : 10.1200/JCO.2016.69.2319

E. Van-dalen, H. Van-der-pal, and L. Kremer, Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy, Cochrane Database of Systematic Reviews [Internet], vol.8, issue.4, p.2016, 2017.
DOI : 10.1002/14651858.CD005008.pub3

J. Van-as, H. Van-den-berg, and E. Van-dalen, Different infusion durations for preventing platinum-induced hearing loss in children with cancer

O. Oberlin, O. Fawaz, A. Rey, P. Niaudet, V. Ridola et al., Available from: http Long-Term Evaluation of Ifosfamide-Related Nephrotoxicity in Children, Cochrane Database of Systematic Reviews, pp.20165350-20165355, 2009.

L. Deley, M. Leblanc, T. Shamsaldin, A. Raquin, M. Lacour et al., Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Soci??t?? Fran??aise d???Oncologie P??diatrique, Journal of Clinical Oncology, vol.21, issue.6, pp.1074-81, 2003.
DOI : 10.1200/JCO.2003.04.100

M. Edelmann, V. Daryani, M. Bishop, W. Liu, T. Brinkman et al., Neurocognitive and patientreported outcomes in adult survivors of childhood Osteosarcoma, JAMA Oncol Feb, vol.12, issue.2, p.201, 2016.

T. John, N. Lomeli, and D. Bota, Systemic cisplatin exposure during infancy and adolescence causes impaired cognitive function in adulthood, Behavioural Brain Research, vol.319, 2006.
DOI : 10.1016/j.bbr.2016.11.013
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332150/pdf